Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 04:00PM ET
18.43
Dollar change
+0.52
Percentage change
2.90
%
IndexRUT P/E- EPS (ttm)-0.62 Insider Own1.20% Shs Outstand128.06M Perf Week3.42%
Market Cap2.37B Forward P/E93.59 EPS next Y0.20 Insider Trans-0.39% Shs Float126.83M Perf Month16.87%
Income-77.73M PEG- EPS next Q0.03 Inst Own97.50% Short Float2.86% Perf Quarter13.00%
Sales644.12M P/S3.67 EPS this Y181.67% Inst Trans-2.42% Short Ratio4.78 Perf Half Y40.05%
Book/sh7.09 P/B2.60 EPS next Y100.94% ROA-4.68% Short Interest3.63M Perf Year0.49%
Cash/sh3.02 P/C6.10 EPS next 5Y- ROE-8.38% 52W Range12.77 - 21.22 Perf YTD13.91%
Dividend Est.- P/FCF- EPS past 5Y- ROI-5.93% 52W High-13.15% Beta1.23
Dividend TTM- Quick Ratio1.91 Sales past 5Y17.35% Gross Margin40.57% 52W Low44.32% ATR (14)0.67
Dividend Ex-Date- Current Ratio1.99 EPS Y/Y TTM20.06% Oper. Margin-13.37% RSI (14)70.50 Volatility4.27% 3.87%
Employees2100 Debt/Eq0.67 Sales Y/Y TTM12.06% Profit Margin-12.07% Recom1.53 Target Price20.62
Option/ShortYes / Yes LT Debt/Eq0.44 EPS Q/Q5.36% Payout- Rel Volume0.87 Prev Close17.91
Sales Surprise0.49% EPS Surprise306.50% Sales Q/Q10.44% EarningsNov 05 BMO Avg Volume758.21K Price18.43
SMA209.77% SMA5022.20% SMA20022.72% Trades Volume662,324 Change2.90%
Date Action Analyst Rating Change Price Target Change
TodayInitiated Jefferies Buy $22
May-01-24Resumed Craig Hallum Buy $26
Dec-29-23Reiterated BTIG Research Buy $25 → $21
Aug-21-23Upgrade Stephens Equal-Weight → Overweight $18
May-16-23Downgrade Raymond James Outperform → Mkt Perform
May-09-23Upgrade BTIG Research Neutral → Buy $25
Feb-24-23Upgrade The Benchmark Company Hold → Buy $20
Feb-01-23Upgrade Needham Hold → Buy $15
Aug-26-22Downgrade The Benchmark Company Buy → Hold
Aug-22-22Downgrade Needham Buy → Hold
Dec-09-24 08:10AM
Dec-05-24 07:00AM
Nov-19-24 08:15AM
Nov-14-24 08:10AM
Nov-08-24 07:00AM
12:00PM Loading…
Nov-06-24 12:00PM
02:24AM
02:07AM
Nov-05-24 10:00AM
07:23AM
07:00AM
Nov-04-24 09:55AM
Oct-23-24 05:37AM
Oct-22-24 08:10AM
Oct-15-24 07:30AM
09:55AM Loading…
Oct-08-24 09:55AM
08:10AM
Sep-23-24 06:47PM
Sep-11-24 08:05AM
Aug-29-24 08:05AM
Jul-29-24 06:00PM
04:33PM
04:05PM
Jul-20-24 08:09AM
Jul-09-24 07:00AM
Jun-13-24 08:00AM
Jun-10-24 01:00AM
May-28-24 08:05AM
May-02-24 02:14PM
May-01-24 03:04AM
11:53AM Loading…
Apr-30-24 11:53AM
11:25AM
10:30AM
08:52AM
08:40AM
07:37AM
07:30AM
Apr-23-24 10:00AM
Apr-18-24 07:05AM
Apr-09-24 07:00AM
Mar-27-24 08:30AM
Mar-20-24 12:00PM
09:55AM
07:00AM
Mar-01-24 07:05AM
Feb-29-24 08:12AM
Feb-28-24 09:55AM
Feb-21-24 09:57AM
06:38AM
Feb-20-24 07:00PM
05:35PM
04:39PM
04:37PM
04:05PM
Feb-01-24 07:05AM
Jan-30-24 09:15AM
07:05AM
Jan-12-24 05:20AM
Jan-02-24 07:05AM
Dec-28-23 04:30PM
03:08PM
12:07PM
08:10AM
Dec-05-23 08:00AM
Nov-14-23 07:00AM
Nov-13-23 09:55AM
Nov-07-23 09:01AM
Nov-06-23 09:00PM
06:10PM
04:33PM
04:05PM
Nov-01-23 10:01AM
Oct-30-23 03:46PM
10:00AM
Oct-27-23 09:55AM
Oct-24-23 07:00AM
05:20AM
02:18AM
Oct-18-23 08:26AM
Oct-17-23 09:20AM
09:15AM
Oct-13-23 12:00PM
Aug-08-23 11:30AM
09:22AM
07:00AM
Jul-27-23 07:00AM
Jul-18-23 07:10AM
Jun-29-23 07:00AM
Jun-21-23 08:00PM
Jun-15-23 04:45PM
Jun-08-23 01:36PM
Jun-06-23 08:02AM
Jun-05-23 07:00AM
Jun-01-23 07:00AM
May-30-23 07:00AM
May-17-23 08:16AM
May-16-23 06:59AM
May-10-23 01:26AM
May-09-23 01:39PM
May-08-23 06:15PM
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Olivo Alicia CGeneral CounselNov 15 '24Sale15.365,17579,47537,129Nov 19 05:43 PM
ALICIA OLIVOOfficerNov 15 '24Proposed Sale15.795,17581,713Nov 15 04:35 PM
Olivo Alicia CGeneral CounselAug 15 '24Sale16.051,04016,69543,813Aug 19 04:17 PM
ALICIA OLIVOOfficerAug 15 '24Proposed Sale15.821,04016,453Aug 15 04:29 PM
BRUCE K CROWTHEROfficerAug 15 '24Proposed Sale15.958,353133,243Aug 15 04:12 PM
Zook Anthony P.DirectorAug 10 '24Option Exercise0.0011,336011,336Aug 13 04:40 PM
TETRAULT LYNN A.DirectorAug 10 '24Option Exercise0.0011,336061,398Aug 13 04:37 PM
Perez David BrianDirectorAug 10 '24Option Exercise0.0011,336021,636Aug 13 04:34 PM
Kelly Michael AaronDirectorAug 10 '24Option Exercise0.0011,336031,755Aug 13 04:32 PM
KANOVSKY STEPHEN MDirectorAug 10 '24Option Exercise0.0011,336036,090Aug 13 04:27 PM
HANNAH ALISON L.DirectorAug 10 '24Option Exercise0.0011,3360118,769Aug 13 04:24 PM
Gunn NeilDirectorAug 10 '24Option Exercise0.0011,336011,336Aug 13 04:21 PM
Floegel ElizabethDirectorAug 10 '24Option Exercise0.0011,336011,336Aug 13 04:17 PM
Olivo Alicia CGeneral CounselMay 15 '24Sale15.741,04916,51144,867May 17 04:07 PM
Smith Christopher MChief Executive OfficerMay 11 '24Option Exercise0.0096,1260679,432May 14 09:39 PM
Olivo Alicia CGeneral CounselMay 11 '24Option Exercise0.0013,004045,916May 14 09:39 PM
Stone WarrenChief Commerical OfficerMay 11 '24Option Exercise0.0019,2240100,658May 14 09:38 PM
Sherman Jeffrey ScottChief Financial OfficerMay 11 '24Option Exercise0.0026,0100148,505May 14 09:38 PM
Harris MelodyChf Ops Off, Pres, InformaticsMay 11 '24Option Exercise0.007,0680110,023May 14 09:38 PM
TETRAULT LYNN A.DirectorMar 04 '24Sale15.976,11297,57950,062Mar 06 04:26 PM
Olivo Alicia CGeneral CounselFeb 15 '24Sale14.962,58738,71334,866Feb 20 04:32 PM